Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IMV Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed,
byBenzinga Newsdesk
February 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (“MVP-S”), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”).

  • Early analysis reveals clinically meaningful activity in refractory DLBCL patients
  • Multiple confirmed complete responses observed in heavily pre-treated patients
  • No adverse safety and tolerability signal reported, consistent with previous clinical trials
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Google’s Winning Streak: An In-Depth Examination Of The Tech Behemoth Alphabet’s Remarkable 35% Surge In Market Value In 2023

By Zaheer Anwari
May 18, 3:03 PM
Bill Ackman has made a noteworthy investment by injecting a staggering $1.1 billion into Alphabet Inc. Alphabet demonstrated resilience, surging past $100 in 2023 after a significant 43% drop in 2022. Despite previous challenges, Ackman's significant investment represents a vote of confidence in Alphabet's robust growth potential.

GOOGL